SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor

Purpose: To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR2285, the first oral coagulation factor XIa (FXIa) inhibitor developed in China in combination with aspirin, clopidogrel or ticagrelor in healthy subjects.Methods: This study was a single-center, randomized, d...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Tingting Ma (Author), Yanli Dong (Author), Lei Huang (Author), Yuanxun Yang (Author), Yan Geng (Author), Fei Fei (Author), Pinhao Xie (Author), Yu Zhao (Author), Hui Lin (Author), Zeyu Yang (Author), Yun Jin (Author), Xitong Ju (Author), Runbin Sun (Author), Juan Li (Author)
Formato: Libro
Publicado: Frontiers Media S.A., 2022-10-01T00:00:00Z.
Subjects:
Acceso en liña:Connect to this object online.
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Internet

Connect to this object online.

3rd Floor Main Library

Detalle de Existencias desde 3rd Floor Main Library
Número de Clasificación: A1234.567
Copia 1 Dispoñible